Sanofi Lays Out Ambitious Plans To Bolster Its Pipeline, Highlights 12 Blockbuster Opportunities

Sanofi SA SNY says it has 12 drugs in development with a blockbuster potential (to make over $1 billion in annual sales), including nine medicines and vaccines, each with €2 billion-€5 billion in peak sales potential.

The company also highlighted three "pipeline-in-a-product" assets with a potential of more than €5 billion in peak sales.

CEO Paul Hudson is confronting mounting investor pressure as shareholders seek concrete details about the company's expanded R&D budget. 

The French drugmaker said it expected its recently launched and future pharmaceutical assets to generate more than €10 billion of annual sales by 2030, in addition to the strong growth of Dupixent and Vaccines.

Sanofi's top-selling drug Dupixent, which it expects to extend its use in treating chronic obstructive pulmonary disease (COPD), often known as "smoker's lung," is expected to deliver low double-digit annual sales growth up to 2030.

Sanofi's R&D will lead to a 50% increase in Phase 3 studies between 2023 and 2025, creating the greatest pipeline momentum in Sanofi's history. 

The company's commitment to R&D will also support an expected 25 mid- to late-stage read-outs and up to 19 regulatory submissions for its pharma assets in the next two years.

Sanofi reiterates its expectation to generate over €10 billion in annual sales by 2030, including the recent launch of Beyfortus, a monoclonal antibody to protect against respiratory syncytial virus complications in infants. 

Concurrently, Sanofi said its Phase 3 IMROZ trial of Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide, and dexamethasone (VRd) met its primary endpoint at a planned interim analysis for efficacy.

The 484-patient study demonstrated a statistically significant improvement in progression-free survival compared with VRd alone in transplant-ineligible patients with newly diagnosed multiple myeloma. 

This is also the second Phase 3 trial investigating Sarclisa in newly diagnosed patients to show superiority versus standard of care.

Price Action: SNY shares closed at $45.98 on Wednesday.